贝伐单抗联合化疗治疗恶性胶质瘤患者的MRI研究 |
| |
引用本文: | Pope W. B. Lai A. Nghiemphu P. 李青波.贝伐单抗联合化疗治疗恶性胶质瘤患者的MRI研究[J].世界核心医学期刊文摘,2006,2(9):19-19. |
| |
作者姓名: | Pope W. B. Lai A. Nghiemphu P. 李青波 |
| |
作者单位: | [1]Department of Radiological Sciences, David Geffen School of Medicine at UCLA Medical Center, BL -428/CHS, 10833 Le Conte Avenue, Los Angeles, CA 90095-1721, United States [2]不详, David Geffen School of Medicine at UCLA Medical Center, BL -428/CHS, 10833 Le Conte Avenue, Los Angeles, CA 90095-1721, United States |
| |
摘 要: | 复发性胶质瘤患者(n=14)接受贝伐单抗联合卡铂、伊立替康或依托泊苷治疗。首次用药后2~6周时对患者进行MRI扫描随访。7例患者的对比一增强MRI显示肿瘤缩小,明显的缩小最早出现在首次治疗后2周。该治疗方案对不均匀对比增强肿瘤的疗效较对比均匀增强肿瘤的疗效更好。
|
关 键 词: | 联合化疗治疗 MRI扫描 贝伐单抗 恶性胶质瘤 复发性胶质瘤 增强MRI 依托泊苷 伊立替康 |
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy |
| |
Abstract: | |
| |
Keywords: | |
本文献已被 CNKI 维普 等数据库收录! |
|